Synexus, a global company that recruits and runs late phase clinical trials, has further strengthened its leadership position in Poland with the acquisition of Warsaw-based Osteomed for an undisclosed sum.

Synexus will combine its own Warsaw facility with Osteome and house it in a new research clinic four times the size of Synexus’ current Warsaw facility.

Christophe Berthoux, CEO of Synexus, said, “Synexus has long recognized the importance of Poland in the global clinical trials market in terms of the significant opportunities this region can offer. We have had a well-established presence in Poland for a number of years but felt that now was the time to further strengthen this, both in recognition of the area as well as in support of our business growth. The acquisition of Osteomed will enhance our capacity, brings us scientific expertise and experience in the field of bone diseases and access to an extensive patient database.”

Analysts have predicted that the global clinical trials market in Poland will grow to reach $323 million by 2015, offering attractive benefits including access to high quality medical expertise, significant cost advantages, a motivated patient population and excellent trial data quality.

”It also creates a third pillar in our global infrastructure,” continued Berthoux. “We have 24 sites across the world and a significant presence in the U.K., Germany and now Poland. Synexus’ success in Poland will be used as a platform to grow our business across Central and Eastern Europe where we already have clinics in Hungary, Ukraine and Bulgaria. This infrastructure enables us to offer scale and capacity to clients as well as stability which are seen as vital by the pharmaceutical industry.”

Owners of Osteomed, Andrzej Sawicki and Piotr Sawicki, will remain with Synexus in senior positions.